Adtraza subcutaneous injection 300 mg pen, manufactured by Leo Pharma, contains Tralokinumab (genetical recombination). This single-use pre-filled pen is indicated for moderate-to-severe atopic dermatitis in adults and adolescents aged 12 years and older who require systemic therapy. It is supplied as a 300mg/2mL kit with YJ code 4490409G2029.
Adtraza subcutaneous injection 300 mg pen
Need more detailed information?
Contact TASAKI PHARMA for product sourcing, availability, or related support (English support available).